Feed aggregator

Limited Competition: Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 Clinical Trial Not Allowed)

NIH Funding Opportunities -

Funding Opportunity RFA-MD-20-007 from the NIH Guide for Grants and Contracts. NIMHD invites applications from eligible institutions to establish a national coordinating center (CC) for NIMHD-funded Research Centers in Minority Institutions (RCMIs). The primary goals of RCMI Specialized Centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that partner with RCMI centers. The RCMI CC will work closely with key personnel at all RCMI sites and with NIMHD staff to promote and facilitate communication and collaboration across RCMI sites nationwide to help them collectively achieve these RCMI program objectives. The RCMI CC will be responsive to requests generated by RCMI site key personnel, NIMHD, NIH, the scientific community, and the general public. Eligible applicant institutions for this FOA are limited to those currently funded by the RCMI program through RFA-MD-17-003, RFA-MD-17-006, or RFA-MD-18-012.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)

NIH Funding Opportunities -

Funding Opportunity PAR-20-118 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies responsive to this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction.

Alzheimers Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)

NIH Funding Opportunities -

Funding Opportunity RFA-AG-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team science strategy and apply high throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements; and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimers disease andrelated dementias (AD/ADRD).

EMERGING FRONTIERS IN RESEARCH AND INNOVATION 2020 (EFRI-2020)

NSF Upcoming Funding Opportunities -

Full Proposal Deadline Date: March 26, 2020
Full Proposal Due Date

Program Guidelines: NSF 19-599

The Emerging Frontiers in Research and Innovation (EFRI) program of the NSF Directorate for Engineering (ENG) serves a critical role in helping ENG focus on important emerging areas in a timely manner. This solicitation is a funding opportunity for interdisciplinary teams of researchers to embark on rapidly advancing frontiers of fundamental engineering research. For this solicitation, we will consider proposals that aim to investigate emerging frontiers in one of the following two research ...
More at https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=13708&WT.mc_id=USNSF_39&WT.mc_ev=click


This is an NSF Upcoming Due Dates item.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U19 Clinical Trial Optional)

NIH Funding Opportunities -

Funding Opportunity PAR-20-119 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional)

NIH Funding Opportunities -

Funding Opportunity RFA-AI-20-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to comprehensively investigate the dynamics and drivers of influenza transmission between humans. This FOA will support research to: (1) improve detection and sampling of influenza viral particles from the air; (2) develop novel assays to assess viability and infectivity of influenza viral particles collected from the air; and (3) comprehensively evaluate the contribution of viral, host, physical, and environmental factors to influenza transmission between humans.

Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed)

NIH Funding Opportunities -

Funding Opportunity RFA-AI-20-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will establish Human Biomimetics for Infectious Diseases Cooperative Research Centers (Biomimetics CRCs) focused on multidisciplinary research advancing and/or developing innovative in vitro human-cell- or -tissue-derived three-dimensional (3D) models for basic and translational research on infectious diseases.

Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional)

NIH Funding Opportunities -

Funding Opportunity RFA-AG-21-016 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for 3-year planning projects for trials in either of two age ranges (25 to 50 or ? 50 years of age) to determine the effects of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. Proposed projects must plan for trials with a minimum of three arms: a control group, a CR group, and at least one other nutritional intervention that modifies level, timing, or composition of nutrient intake. Narrower age ranges within the younger and older age groups may be proposed. The projects will support organizational, planning, and protocol development activities, addressing elements such as selection and design of interventions, recruitment, eligibility criteria, selection of pre-specified study outcomes, outcome ascertainment, behavioral interventions to achieve and maintain adherence, adherence measurement, and outcome analysis. The projects will also support pilot studies and data analyses needed for these planning activities.

Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

NIH Funding Opportunities -

Funding Opportunity PAR-20-117 from the NIH Guide for Grants and Contracts. The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.

Pages

Subscribe to Ciencia Puerto Rico aggregator